Try our Advanced Search for more refined results

Staublein v. Acadia Pharmaceuticals Inc. et al

  1. June 02, 2020

    Acadia Can't Slip Investor Suit Over Parkinson's Drug Deaths

    Acadia Pharmaceuticals escaped part of the securities fraud claims lodged in a proposed class action over its alleged cover-up of fatality risks associated with its Parkinson's disease treatment, but it must still face the bulk of the suit, a California federal court ruled Monday.

  2. June 10, 2019

    Acadia Tries To Nix Investor Suit Over Drug Deaths

    Acadia Pharmaceuticals on Friday sought to dismiss a proposed class action accusing it of inflating its stock price by hiding safety risks connected to its medication for hallucinations and delusions, telling a California federal judge that a government investigation into reported patient deaths confirmed the treatment was safe.

  3. February 27, 2019

    Pomerantz To Rep Investors In Acadia Drug Deaths Case

    Pomerantz LLP has been appointed as lead counsel in a proposed securities fraud class action alleging Acadia Pharmaceuticals Inc. inflated its stock price by hiding safety risks and downplaying reports of deaths connected to its flagship drug used to treat hallucinations and delusions, Nuplazid.

  4. July 20, 2018

    Acadia Hit With Securities Suit Over Drug Linked To Deaths

    An Acadia Pharmaceuticals Inc. shareholder slapped the biopharmaceutical company with a putative securities fraud class action in California federal court Thursday, claiming the company inflated its stock price by hiding safety risks and downplaying reports of deaths connected to its treatment for hallucinations and delusions.